Authors
Latest:
Easing the Path to ProfitabilitySteps for startups in tapping non-dilutive financing options.
Latest:
Maximizing the Chance of Launch Success with Orphan DrugsIn preparing to launch a rare-disease medication, it is important to understand the needs in the therapy area and invest strategically to maximize the impact on the unique rare-disease environment.
Latest:
Data As Currency: The Value of Longitudinal Data for PharmaLongitudinal databases can have several advantages for pharma companies in comparison to collecting data from clinical trials alone.
Latest:
Real-Time Information across the Pharma Supply ChainTim Willis and Oliver Wack outline the role of alternative data in supply chain risk management, and the ancillary benefits that come from adopting such technology.
Latest:
Closing the Loop: Manufacturing & Regulatory Functions as Data CollaboratorsInformation gaps between manufacturing and regulatory, between ERP and RIM systems, are preventing all the practical and strategic benefits of data-based collaboration, writes Catherine Gambert.
Latest:
What the Purdue Pharma Case Teaches Us About Reputational TornadoesPurdue Pharma and its corporate leadership featured prominently in the media recently as litigation mounts over their sales and marketing of Oxycontin. Nir Kossovsky offers some observations about the lessons this situation provides for all corporate leaders responsible for their companies’ reputations.
Latest:
The Implications of Connected Medical Devices & Digital HealthcareLoetitia Jabri considers the broader implications as healthcare providers embraces new digital connectivity options as part of the Medicine 2.0 era.
Latest:
The Patient Comes First with Outcomes-Based ContractingThe benefits and challenges of outcomes-based contracting.
Latest:
Making the Leap from Pharmaceuticals to Private Equity, Venture CapitalA Harvard Business School Healthcare Alumni Association Q&A with Jeremy Goldberg of Arsenal Capital Partners.
Latest:
Are Pharma Marketers Fighting the Last War?Despite being the fastest growing influencers in healthcare, ad campaigns targeted at payers are often an afterthought.
Latest:
Cystic Fibrosis: The Importance of Patient AdvocacyThe importance of patient advocacy in boosting research for cystic fibrosis.
Latest:
Three Tips to Managing Multiple Agency PartnersOutlining three practices that are key to navigating today’s multiplayer agency landscape - and getting more value from each external vendor.
Latest:
The Path to Patient-Focused AccountabilityBenchmark survey assesses the industry’s progress so far in moving from words to action in its approach to patient centricity.
Latest:
Patient Support Programs: Cost, Benefit, and ResourcingWorking group explores the challenges of patient support programs (PSPs) and market research programs (MRPs) for pharmacovigilance (PV) professionals-and solutions currently being put into practice.
Latest:
Patient Support Programs: Cost, Benefit, and ResourcingWorking group explores the challenges of patient support programs (PSPs) and market research programs (MRPs) for pharmacovigilance (PV) professionals-and solutions currently being put into practice.
Latest:
Patient Support Programs: Cost, Benefit, and ResourcingWorking group explores the challenges of patient support programs (PSPs) and market research programs (MRPs) for pharmacovigilance (PV) professionals-and solutions currently being put into practice.
Latest:
FDA Modernizes Controlled Correspondence Interactions with Pharma IndustryAs part of FDA’s ongoing effort to modernize interactions with industry, FDA launched a portal to help with submissions of controlled correspondence via email instead of manual data entry.
Latest:
FDA Modernizes Controlled Correspondence Interactions with Pharma IndustryAs part of FDA’s ongoing effort to modernize interactions with industry, FDA launched a portal to help with submissions of controlled correspondence via email instead of manual data entry.
Latest:
How Blockchain Can Support FDA’s AgendaThe digitization of healthcare is paving the way to accelerate drug development in the industry, and the FDA is doing its best to support industry.
Latest:
Pharma's Incentive Compensation Plan LandscapeAs pharmaceutical companies become increasingly focused on retaining key sales people, they continually consider ways to leverage variable compensation as a strategic tool for maximizing the return on their investment in top talent.
Latest:
“Drug Transparency”: Each Bill Needs Careful EvaluationCould the new Vermont Drug Transparency law “lead the US Pharmaceutical industry to an awful end”? Tom Norton reports.
Latest:
M&A: Range of Fundamental Factors Will Drive Strong Deal FlowThe outlook for pharma M&A continues to be strong, writes Michael Jewell.
Latest:
RAPS Statement - BREXIT delayRegulatory Affairs Professionals Society's Executive Director, Paul Brooks, discusses the looming uncertainty about what will happen after the UK leaves the European Union as many important details remain unclear.
Latest:
Measuring Product-Market-FitJean-Francois Denault outlines a systemic approach to evaluating the commercial viability of a product.
Latest:
Work Planning and Approaches to Overcome Bottlenecks – an analytical department in drug developmentCommon strategies to overcome bottlenecks and how fast they might lead to results are discussed.
Latest:
Primed for Progress: FDA’s Pre-Cert Program for Digital Health DevicesExecutives from DIA, Ranjini Prithviraj and Sudip Parikh discuss documents the FDA released that further detail the agency’s implementation plan for its Software Precertification Pilot Program.
Latest:
Primed for Progress: FDA’s Pre-Cert Program for Digital Health DevicesExecutives from DIA, Ranjini Prithviraj and Sudip Parikh discuss documents the FDA released that further detail the agency’s implementation plan for its Software Precertification Pilot Program.
